<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119710">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544478</url>
  </required_header>
  <id_info>
    <org_study_id>V501-110</org_study_id>
    <secondary_id>132247</secondary_id>
    <nct_id>NCT01544478</nct_id>
  </id_info>
  <brief_title>V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)</brief_title>
  <official_title>A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long term safety of quadrivalent Human Papillomavirus (HPV)
      types 6, 11, 16, 18 vaccine and its effectiveness in the prevention of cervical
      intraepithelial neoplasia (CIN), adenocarcinoma in situ, and cervical cancer related to HPV
      in Japanese women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2011</start_date>
  <completion_date type="Actual">August 27, 2016</completion_date>
  <primary_completion_date type="Actual">August 27, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of CIN 2/3 or worse related to HPV type 6, 11, 16, or 18</measure>
    <time_frame>Up to Month 48 postvaccination</time_frame>
    <description>Pathology panel consensus diagnosis of CIN 2 or 3, adenocarcinoma in situ, invasive squamous cervical carcinoma, or invasive adenocarcinoma of the cervix, AND HPV type 6, 11, 16, or 18 detected in an adjacent section from the same tissue block</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1030</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Adenocarcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>V501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V501</intervention_name>
    <description>Human Papillomavirus types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6</description>
    <arm_group_label>V501</arm_group_label>
    <other_name>Gardasil™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese females

          -  Not pregnant at Screening and agree to use effective contraception through Month 7 of
             the study

          -  Lifetime history of 0 to 4 male or female sexual partners

          -  No oral temperature ≥37.5 centigrade within 24 hours prior to injection

        Exclusion Criteria:

          -  Received a marketed HPV vaccine

          -  Prior abnormal papanicolaou smear (PAP) or biopsy showing CIN

          -  Known history of positive test for HPV

          -  Known history of genital warts

          -  Received immune globulin or blood products within 6 months prior to first injection
             or plan to receive any through Month 7 of the study

          -  History of splenectomy, known immune disorders, or receiving immunosuppressives

          -  Immunocompromised or diagnosed as having human immunodeficiency virus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>February 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Adenocarcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
